Galli M - Search Results

1

Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.

Bonora S, Calcagno A, Vigano O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G, Rusconi S. Bonora S, et al. Among authors: galli m. Curr HIV Res. 2014;12(5):339-46. doi: 10.2174/1570162x12666140807151616. Curr HIV Res. 2014. PMID: 25106410

2

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).

Bonora S, Rusconi S, Calcagno A, Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G. Bonora S, et al. Among authors: galli m. J Antimicrob Chemother. 2015 Nov;70(11):3096-9. doi: 10.1093/jac/dkv208. Epub 2015 Jul 14. J Antimicrob Chemother. 2015. PMID: 26174719 Free article. Clinical Trial.

3

Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.

Castagna A, Ferrara M, Galli L, Comi L, Sterrantino G, Cenderello G, Zaccarelli M, Focà E, Roncadori A, Lazzarin A; PRESTIGIO Study Group. Castagna A, et al. Among authors: galli l. J Antimicrob Chemother. 2018 Jan 1;73(1):177-182. doi: 10.1093/jac/dkx371. J Antimicrob Chemother. 2018. PMID: 29077927

4

Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Kurtagic S, Galazzi M, Croce F, Moroni M, Galli M. Rusconi S, et al. Among authors: galli m. Antivir Ther. 2001 Mar;6(1):41-6. Antivir Ther. 2001. PMID: 11417760

5

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.

Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. Meini G, et al. J Antimicrob Chemother. 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23. J Antimicrob Chemother. 2014. PMID: 24155059 Free PMC article.

6

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Mocroft A, et al. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Lancet HIV. 2016. PMID: 26762990 Clinical Trial.

7

Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.

Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M. Rusconi S, et al. Among authors: galli m. Antivir Ther. 1996 Dec;1(4):211-9. Antivir Ther. 1996. PMID: 11324823

8

In vitro antibody production (IVAP) in the follow-up of pediatric human immunodeficiency virus type 1-infected patients.

Rusconi S, Riva A, Cocchi F, Massironi E, Tornaghi R, de Maddalena C, de Pasquale MP, Galli M. Rusconi S, et al. Among authors: galli m. Pediatr AIDS HIV Infect. 1997 Apr;8(2):127-9. Pediatr AIDS HIV Infect. 1997. PMID: 11361779 No abstract available.

9

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.

Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group. Marchetti G, et al. BMC Infect Dis. 2014 Feb 12;14:79. doi: 10.1186/1471-2334-14-79. BMC Infect Dis. 2014. PMID: 24520976 Free PMC article.

10

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group. Achhra AC, et al. HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28. HIV Med. 2016. PMID: 26216031 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,061 results

Search Page

Filters